ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma
To evaluate the prognostic significance of DNA excision repair gene polymorphisms, excision repair cross-complementation group 1 (ERCC1) and X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1) polymorphisms were investigated in Japanese patients with head and neck squamous cell carcinoma (HNSCC).
A total of 225 consecutive patients with HNSCC who underwent surgery or chemoradiotherapy/radiotherapy (CRT/RT) with curative intent as primary treatment from 2006 to 2017 were recruited. ERCC1 C8092A and XRCC1 Arg399Gln polymorphisms in DNA extracted from individual blood samples were determined by the polymerase chain reaction-restriction fragment length polymorphism method. Cumulative survival was estimated by Kaplan–Meier analysis with a log-rank test and Cox proportional hazards model stratified by treatment arm, adjusting for clinical prognostic factors.
Multivariate analysis showed that carriers with the ERCC1 8092 (C/A+A/A) genotype (hazard ratio, 3.56; 95% confidence interval, 1.22–7.39; p = 0.02) had significantly worse survival than those with ERCC1 8092 C/C who received CRT/RT. Conversely, the XRCC1 Arg399Gln polymorphism did not influence survival in patients who received CRT/RT as well as surgery.
The ERCC1 C8092A polymorphism might be an independent predictor of response to CRT and survival outcome in patients with HNSCC. This is the first report to investigate the role of DNA excision repair gene polymorphisms in patients with head and neck cancer in a Japanese population.
KeywordsDNA repair Single nucleotide polymorphism Survival Head and neck cancer Japanese
This work was supported by JSPS KAKENHI Grant Number (JP17K11391) (Grant-in-Aid for Scientific Research C).
- 4.Chitapanarux I, Tharavichitkul E, Lorvidhaya V, Sittitrai P, Pattarasakulchai T (2010) Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer. Biomed Imaging Interv J 6(3):e23PubMedPubMedCentralCrossRefGoogle Scholar
- 10.Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomark Prev 11(12):1513–1530Google Scholar
- 16.Bisof V, Zajc Petranovic M, Rakusic Z, Samardzic KR, Juretic A (2016) The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. Eur Arch Otorhinolaryngol 273(9):2305–2317PubMedCrossRefGoogle Scholar
- 17.Vaezi A, Feldman CH, Niedernhofer LJ (2011) ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmgenom Pers Med 4:47–63Google Scholar
- 19.Han Y, Liu J, Sun M, Zhang Z, Liu C, Sun Y (2016) A significant statistical advancement on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer: an updated meta-analysis. Dis Markers 2016:7643981PubMedPubMedCentralGoogle Scholar
- 21.Quintela-Fandino M, Hitt R, Medina PP et al (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24(26):4333–4339PubMedCrossRefGoogle Scholar
- 33.Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88(13):890–899PubMedCrossRefGoogle Scholar
- 40.Yang P, Ho JW, Zomaya AY, Zhou BB (2010) A genetic ensemble approach for gene-gene interaction identification. 29(11):524Google Scholar